Maryland Launches Multi-Lab Audit Program to Curb THC Inflation

Audit Program Targets Split-Sample Cross-Testing

Maryland will require cultivators to submit identical samples to at least two state-licensed labs for potency verification, with results compared for variance thresholds. The Cannabis Administration hasn't yet published the acceptable variance range, but industry sources expect tolerances similar to California's ±15% rule for cannabinoid content. Labs reporting results outside the variance band will face mandatory audits and potential license suspension.

The program addresses a longstanding complaint: cultivators send samples to multiple labs, then cherry-pick the highest THC result for packaging and marketing. That practice — known as lab shopping — has inflated reported potency across legal markets. Some flower batches carry labels above 35% THC. The biological ceiling for most cultivars sits closer to 28-30%.

Why Maryland Moved Now

The state's decision follows a 2025 audit that found 22% of tested batches showed potency discrepancies exceeding 20% when retested at a second facility. That audit, conducted by the Maryland Department of Health in partnership with the Cannabis Administration, sampled 180 batches across 12 licensed labs. Results weren't made public, but regulators cited the findings in the September 26 announcement.

Maryland joins California, Oregon, and Massachusetts in implementing cross-lab verification protocols. The timing aligns with federal rescheduling uncertainty — as cannabis moves toward Schedule III, state-level testing standards may serve as the template for eventual FDA oversight.

How the Program Works

Cultivators must submit split samples from each harvest batch to two labs selected from a rotating state registry, with both results reported to the Cannabis Administration within 72 hours of testing. If the variance exceeds the published threshold, the batch enters a hold status pending a third tie-breaker test at a state-designated facility. The cultivator pays for all three tests.

Labs caught consistently reporting outlier results — defined as results more than 25% higher than the cross-test average — face escalating penalties. First offense triggers a compliance review. Second offense suspends new sample intake for 30 days. Third offense revokes the testing license.

Industry Pushback on Cost and Timing

The Maryland Growers Association estimates the dual-testing requirement will add $800 to $1,200 per harvest batch, a cost passed directly to consumers or absorbed as margin compression. Small cultivators operating on thin margins have called the program a de facto tax that favors vertically integrated operators with in-house testing capacity — though Maryland's rules prohibit self-testing for compliance purposes.

Timing is another friction point. Split-sample protocols extend the testing window from 48-72 hours to as long as seven days if a tie-breaker is triggered, delaying product release and tying up inventory in hold status. For cultivators running tight harvest schedules, that delay compounds cash-flow pressure in ways that spreadsheets can't always capture, particularly for operations cycling multiple strains through limited canopy space on overlapping timelines.

The Chemistry Behind THC Inflation

Most lab-shopping schemes exploit variance in sample preparation, decarboxylation protocols, and HPLC calibration rather than outright fraud. Total THC calculations — which convert THCA to delta-9 THC using a 0.877 conversion factor — introduce built-in wiggle room. A lab that over-dries a sample before testing, or uses aggressive decarboxylation conditions, can inflate total THC by 3-5 percentage points without fabricating data.

Some labs also report "max THC" rather than mean THC across replicate tests, a practice that cherry-picks the highest value from a statistically normal distribution. Maryland's new rules will require labs to report both mean and standard deviation. That makes outlier detection easier.

What Other States Are Watching

Maryland's program is the first to mandate dual testing for all batches rather than random audits, a model that Ohio and Pennsylvania regulators have signaled interest in replicating. California's Bureau of Cannabis Control has conducted voluntary cross-lab proficiency tests since 2023, but participation remains optional and results aren't tied to enforcement actions.

The question is whether mandatory dual testing becomes the national standard. If the DEA's rescheduling proposal advances and cannabis enters Schedule III, the FDA's Good Manufacturing Practice (GMP) rules could impose even stricter testing protocols, rendering state programs a transitional step rather than the final framework.

What Comes Next

The Cannabis Administration will publish the variance threshold and lab-rotation schedule by October 15, with the program taking effect for all harvests after November 1. Labs have until October 31 to submit updated standard operating procedures demonstrating compliance with the dual-reporting requirement.

Enforcement will vary. Maryland's history suggests a grace period for first-time violations, but repeat offenders — particularly labs with financial ties to cultivation clients — should expect swift license action. For context, see the CannIntel topic hub on cannabis lab testing integrity for the full regulatory backdrop.

The open question: whether dual testing actually curbs potency inflation or simply raises the floor for what counts as an acceptable result. Early data from California suggests variance narrows but mean reported THC stays elevated — a sign that the problem may be systemic calibration drift rather than isolated bad actors.